478837-59-1

Basic information

• Product Name: 5-AMINO-3-BROMO (1H)INDAZOLE
• Synonyms: 3-BroMo-1H-indazol-5-ylaMine;5-AMINO-3-BROMO (1H)INDAZOLE;5-AMINO-3-BROMOINDAZOLE;3-bromo-1H-indazol-5-amine;1H-Indazol-5-aMine, 3-broMo-
• CAS NO: 478837-59-1
• Molecular Formula: C₇H₆BrN₃
• Molecular Weight: 212.05
• Product Categories: CHIRAL CHEMICALS
• Mol File: 478837-59-1.mol
• Article Data: 6

Chemical Properties

• Boiling Point: 431.342 °C at 760 mmHg
• Flash Point: 214.668 °C
• Appearance: /
• Density: 1.867 g/cm³
• Vapor Pressure: 0mmHg at 25°C
• Refractive Index: 1.8
• Storage Temp.: under inert gas (nitrogen or Argon) at 2–8 °C
• PKA: 12.34±0.40(Predicted)
• CAS DataBase Reference: 5-AMINO-3-BROMO (1H)INDAZOLE(CAS DataBase Reference)
• NIST Chemistry Reference: 5-AMINO-3-BROMO (1H)INDAZOLE(478837-59-1)
• EPA Substance Registry System: 5-AMINO-3-BROMO (1H)INDAZOLE(478837-59-1)

Safety Data

• RIDADR: UN2811
• Hazardous Substances Data: 478837-59-1(Hazardous Substances Data)

Usage

Description

5-AMINO-3-BROMO (1H)INDAZOLE is a chemical compound with the molecular formula C7H7BrN4. It is a derivative of indazole, a tricyclic aromatic compound, and features a bromine atom at the 3-position and an amino group at the 5-position. 5-AMINO-3-BROMO (1H)INDAZOLE is known for its potential applications in the synthesis of various pharmaceutical agents and as a reagent in organic chemistry.

Uses

Used in Pharmaceutical Industry:
5-AMINO-3-BROMO (1H)INDAZOLE is used as a reagent for the preparation of polycyclic indazole derivatives, which are known as ERK inhibitors. These inhibitors play a crucial role in the treatment and prevention of cancer by targeting the extracellular signal-regulated kinase (ERK) pathway, a key component in cell growth and proliferation.
Additionally, 5-AMINO-3-BROMO (1H)INDAZOLE is used in the synthesis of anilinoquinazolines, which are antitumor agents. These agents have the potential to inhibit the growth of cancer cells and can be used in the development of novel therapeutic strategies for cancer treatment.

InChI:InChI=1/C7H6BrN3/c8-7-5-3-4(9)1-2-6(5)10-11-7/h1-3H,9H2,(H,10,11)

Upstream product

• 67400-25-3 3-bromo-5-nitro-1H-indazole 
• 5401-94-5 5-nitroindazole 

Downstream Products

• 942189-38-0 1-{2-oxo-2-[4-(4-pyrimidin-2-yl-phenyl)-piperazin-1-yl]-ethyl}-pyrrolidine-3-carboxylic acid (3-bromo-1H-indazol-5-yl)-amide 
• 1279871-80-5 N-(3-bromo-1H-indazol-5-yl)-2-methylsulfonylbenzenesulfonamide 
• 395099-05-5 3-phenyl-1H-indazol-5-amine 
• 1176588-15-0 C₁₄H₁₃N₃O 
• 770701-75-2 5-amino-3-(4-methoxyphenyl)-1H-indazole 
• 1176546-64-7 C₁₄H₁₃N₃ 
• 1175793-77-7 C₁₄H₁₃N₃ 
• 1176630-17-3 C₁₄H₁₃N₃ 
• 1175859-35-4 3-(2-fluorophenyl)-1H-indazol-5-amine 
• 395099-48-6 3-(4-fluoro-phenyl)-1H-indazol-5-ylamine 
• 1356087-71-2 C₁₄H₁₀N₄ 

Relevant articles and documents

INDAZOLES AND AZAINDAZOLES AS LRRK2 INHIBITORS

The present invention is directed to indazole and azaindazole compounds which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

FUSED TETRAZOLES AS LRRK2 INHIBITORS

The present invention is directed to fused tetrazoles of formula (IA) which are inhibitors of LRRK2 and are useful in the treatment of CNS disorders.

POLYCYCLIC INDAZOLE DERIVATIVES THAT ARE ERK INHIBITORS

Disclosed are the ERK inhibitors of formula 1.0 and the pharmaceutically acceptable salts and solvates thereof. Q is a piperidine or piperazine ring that can have a bridge or a fused ring. The piperidine ring can have a double bond in the ring. All other substitutents are as defined herein. Also disclosed are methods of treating cancer using the compounds of formula 1.0.